Bank of Montreal’s GT Biopharma GTBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-433
Closed -$8.51K – 3858
2025
Q4
$8.51K Sell
433
-3,268
-88% -$58K ﹤0.01% 3436
2025
Q3
$54.6K Hold
3,701
– – ﹤0.01% 3097
2025
Q2
$331K Buy
3,701
+3,115
+532% +$201K ﹤0.01% 2535
2025
Q1
$32.8K Sell
586
-572
-49% -$33.6K ﹤0.01% 3139
2024
Q4
$88.3K Sell
1,158
-37
-3% -$2.5K ﹤0.01% 2983
2024
Q3
$63K Hold
1,195
– – ﹤0.01% 3364
2024
Q2
$93.2K Buy
1,195
+400
+50% +$35.8K ﹤0.01% 3257
2024
Q1
$102K Hold
795
– – ﹤0.01% 3280
2023
Q4
$170K Hold
795
– – ﹤0.01% 3188
2023
Q3
$167K Hold
795
– – ﹤0.01% 3129
2023
Q2
$262K Buy
795
+186
+31% +$48.2K ﹤0.01% 3053
2023
Q1
$320K Buy
+609
New +$349K ﹤0.01% 2745

Other funds holding GTBP

Bank of Montreal's GTBP Position: Q1 2026 in Review

Bank of Montreal sold out of GT Biopharma (GTBP) in Q1 2026, closing a stake of 433 shares — an estimated $8.51K sold.

Bank of Montreal first reported a position in GTBP in Q1 2023 and held it in 12 quarters. The position peaked at $331K in Q2 2025. 40 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Bank of Montreal reported no remaining GT Biopharma position as of Q1 2026 after selling out during the quarter.
  • Bank of Montreal sold 433 GT Biopharma shares in Q1 2026, an estimated $8.51K.
  • Bank of Montreal first reported a position in GT Biopharma in Q1 2023 and held it in 12 quarters.
  • Bank of Montreal's GT Biopharma position peaked at $331K in Q2 2025.
  • 40 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.